Evaluation in Nonhuman Primates of Vaccines against Ebola Virus

• DOI: 10.3201/eid0805.010284
• Publication Date: 2012-04-18T17:57:56Z
• Authors: Thomas W. Geisbert; Peter Pushko; Kevin Anderson; Jonathan Smith; Kelly J. Davis; Peter B. Jahrling
• Keywords: Ebolavirus; Nucleoprotein; Ebola vaccine; Ebola Hemorrhagic Fever

Abstract Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects primates vaccine strategies had protected mice guinea pigs from lethal EBOV infection. The following immunogens were used: RNA replicon particles derived an attenuated strain Venezuelan equine encephalitis (VEEV) expressing glycoprotein nucleoprotein; recombinant Vaccinia glycoprotein; liposomes containing lipid A inactivated EBOV; a concentrated, whole-virion preparation. None these successfully robust challenge with EBOV. disease observed differed rodents, suggesting rodent models may not predict efficacy candidate protection require different mechanisms.